Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Whatcott, Clifford J ^a   Ng, Serina ^a   Barrett, Michael T ^b   Hostetter, Galen ^c   Von Hoff, Daniel D ^a   Han, Haiyong ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FASUDIL; GEMCITABINE; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; RHO KINASE; UNCLASSIFIED DRUG; ROCK1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER TISSUE; CELL ACTIVATION; CHROMOSOME 18Q; COCULTURE; COLLAGEN METABOLISM; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG TUMOR LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE AMPLIFICATION; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; MALE; MIGRATION INHIBITION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PANCREATIC STELLATE CELL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENE SILENCING; GENETICS; METABOLISM; METASTASIS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; STROMA CELL;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; COMPARATIVE GENOMIC HYBRIDIZATION; GENE SILENCING; HUMANS; MICE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; STROMAL CELLS;

EID: 85029152594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0183871     Document Type: Article

References (52)

1. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003; 4: 446–456. https://doi.org/10.1038/nrm1128 PMID: 12778124
2. Schofield AV, Bernard O. Rho-associated coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem Mol Biol. 2013; 48: 301–316. https://doi.org/10.3109/10409238.2013.786671 PMID: 23601011
3. Herpin A, Cunningham C. Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J. 2007; 274: 2977–2985. https://doi.org/10.1111/j.1742-4658.2007.05840.x PMID: 17521337
4. Papadimitriou E, Kardassis D, Moustakas A, Stournaras C. TGFβ-induced early activation of the small GTPase RhoA is Smad2/3-independent and involves Src and the guanine nucleotide exchange factor Vav2. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2011; 28: 229–238. https://doi.org/10.1159/000331734 PMID: 21865730
5. Smith PC, Cáceres M, Martinez J. Induction of the myofibroblastic phenotype in human gingival fibroblasts by transforming growth factor-beta1: role of RhoA-ROCK and c-Jun N-terminal kinase signaling pathways. J Periodontal Res. 2006; 41: 418–425. https://doi.org/10.1111/j.1600-0765.2006.00886.x PMID: 16953819
6. Vardouli L, Moustakas A, Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cyto-skeleton reorganization induced by transforming growth factor-beta. J Biol Chem. 2005; 280: 11448–11457. https://doi.org/10.1074/jbc.M402651200 PMID: 15647284
7. Kaneko K, Satoh K, Masamune A, Satoh A, Shimosegawa T. Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro. Pancreas. 2002; 24: 251–257. PMID: 11893932
8. Provenzano PP, Inman DR, Eliceiri KW, Trier SM, Keely PJ. Contact guidance mediated three-dimensional cell migration is regulated by Rho/ROCK-dependent matrix reorganization. Biophys J. 2008; 95: 5374–5384. https://doi.org/10.1529/biophysj.108.133116 PMID: 18775961
9. Yen TW f, Aardal NP, Bronner MP, Thorning DR, Savard CE, Lee SP, et al. Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery. 2002; 131: 129–134. PMID: 11854689
10. Masamune A, Watanabe T, Kikuta K, Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2009; 7: S48–54. https://doi.org/10.1016/j.cgh.2009.07.038 PMID: 19896099
11. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J Off Publ Fed Am Soc Exp Biol. 2008; 22: 276–284. https://doi.org/10.1096/fj.07-9150com PMID: 17761521
12. Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015; 21: 3561–3568. https://doi.org/10.1158/1078-0432.CCR-14-1051 PMID: 25695692
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7–30. https://doi.org/10.3322/caac.21332 PMID: 26742998
14. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817–1825. https://doi.org/10.1056/NEJMoa1011923 PMID: 21561347
15. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691–1703. https://doi.org/10.1056/NEJMoa1304369 PMID: 24131140
16. Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010; 29: 2591–2598. https://doi.org/10.1038/onc.2010.3 PMID: 20140017
17. Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol. 2008; 33: 585–593. PMID: 18695890
18. Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, et al. ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res Off Publ Orthop Res Soc. 2011; 29: 1259–1266. https://doi.org/10.1002/jor.21403 PMID: 21387396
19. Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res. 2004; 64: 5659–5663. https://doi.org/10.1158/0008-5472.CAN-04-0807 PMID: 15313904
20. Kolar C, Caffrey T, Hollingsworth M, Scheetz M, Sutherlin M, Weide L, et al. Duct epithelial cells cultured from human pancreas processed for transplantation retain differentiated ductal characteristics. Pancreas. 1997; 15: 265–271. PMID: 9336790
21. Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A. 2011; 108: 12054–12059. https://doi.org/10.1073/pnas.1104009108 PMID: 21730190
22. Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz RM, et al. Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PloS One. 2012; 7: e32783. https://doi.org/10.1371/journal.pone.0032783 PMID: 22396793
23. Pham N-A, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao M-S, et al. Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol. 2007; 2: 8. https://doi.org/10.1186/1746-1596-2-8 PMID: 17326824
24. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2011; 17: 2744–2756. https://doi.org/10.1158/1078-0432.CCR-10-2214 PMID: 21385921
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82: 1107–1112. PMID: 2359136
26. Garton AJ, Castaldo L, Pachter JA. Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases. Methods Enzymol. 2008; 439: 491–500. https://doi.org/10.1016/S0076-6879(07)00433-8 PMID: 18374184
27. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leuco-cytes. J Exp Med. 1962; 115: 453–466. PMID: 13872176
28. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7: 469–483. https://doi.org/10.1016/j.ccr.2005.04.023 PMID: 15894267
29. Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, et al. A novel method for quantification of gemcitabine and its metabolites 2’,2’-difluorodeoxyuridine and gemcitabine triphos-phate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemother Pharmacol. 2011; 68: 1243–1253. https://doi.org/10.1007/s00280-011-1613-0 PMID: 21431415
30. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324: 1457–1461. https://doi.org/10.1126/science.1171362 PMID: 19460966
31. Lipson D, Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol J Comput Mol Cell Biol. 2006; 13: 215–228. https://doi.org/10.1089/cmb.2006.13.215 PMID: 16597236
32. Gabet A-S, Coulon S, Fricot A, Vandekerckhove J, Chang Y, Ribeil J-A, et al. Caspase-activated ROCK-1 allows erythroblast terminal maturation independently of cytokine-induced Rho signaling. Cell Death Differ. 2011; 18: 678–689. https://doi.org/10.1038/cdd.2010.140 PMID: 21072057
33. Hirooka Y, Shimokawa H. Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs Drugs Devices Interv. 2005; 5: 31–39.
34. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002; 93: 225–232. PMID: 12191614
35. Masamune A, Kikuta K, Satoh M, Satoh K, Shimosegawa T. Rho kinase inhibitors block activation of pancreatic stellate cells. Br J Pharmacol. 2003; 140: 1292–1302. https://doi.org/10.1038/sj.bjp.0705551 PMID: 14581180
36. Haudek SB, Gupta D, Dewald O, Schwartz RJ, Wei L, Trial J, et al. Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovasc Res. 2009; 83: 511–518. https://doi.org/10.1093/cvr/cvp135 PMID: 19406912
37. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006; 290: C661–668. https://doi.org/10.1152/ajpcell.00459.2005 PMID: 16469861
38. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008; 14: 5995–6004. https://doi.org/10.1158/1078-0432.CCR-08-0291 PMID: 18829478
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
40. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012; 109: 15101–15108. https://doi.org/10.1073/pnas.1213353109 PMID: 22932871
41. Adrian K, Strouch MJ, Zeng Q, Barron MR, Cheon EC, Honasoge A, et al. Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Res. 2009; 69: 9169–9174. https://doi.org/10.1158/0008-5472.CAN-09-1705 PMID: 19951995
42. Grzesiak JJ, Ho JC, Moossa AR, Bouvet M. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas. 2007; 35: 293–301. https://doi.org/10.1097/mpa.0b013e31811f4526 PMID: 18090233
43. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S, et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. 2000; 910: 106-118-120.
44. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009; 125: 2323–2331. https://doi.org/10.1002/ijc.24573 PMID: 19598259
45. Naber HPH, ten Dijke P, Pardali E. Role of TGF-beta in the tumor stroma. Curr Cancer Drug Targets. 2008; 8: 466–472. PMID: 18781893
46. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25: 719–734. https://doi.org/10.1016/j.ccr.2014.04.005 PMID: 24856586
47. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25: 735–747. https://doi.org/10.1016/j.ccr.2014.04.021 PMID: 24856585
48. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62: 112–120. https://doi.org/10.1136/gutjnl-2012-302529 PMID: 22466618
49. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21: 418–429. https://doi.org/10.1016/j.ccr.2012.01.007 PMID: 22439937
50. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anticancer drug delivery. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2007; 10: 109–120. https://doi.org/10.1016/j.drup.2007.03.001 PMID: 17452119
51. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013; 4: 2516. https://doi.org/10.1038/ncomms3516 PMID: 24084631
52. Rath N, Morton JP, Julian L, Helbig L, Kadir S, McGhee EJ, et al. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol Med. 2017; 9: 198–218. https://doi.org/10.15252/emmm.201606743 PMID: 28031255